MiMedx (MDXG)
Market Price (6/22/2026): $3.675 | Market Cap: $545.5 MilSector: Health Care | Industry: Biotechnology
MiMedx (MDXG)
Market Price (6/22/2026): $3.675Market Cap: $545.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.6%, FCF Yield is 12% Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -26% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -42% Low stock price volatilityVol 12M is 43% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Weak multi-year price returns2Y Excs Rtn is -85%, 3Y Excs Rtn is -110% | Weak revenue growthRev Chg QQuarterly Revenue Change % is -33% Key risksMDXG key risks include [1] its history of financial fraud allegations, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.6%, FCF Yield is 12% |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -26% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 18%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 17% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -42% |
| Low stock price volatilityVol 12M is 43% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -85%, 3Y Excs Rtn is -110% |
| Weak revenue growthRev Chg QQuarterly Revenue Change % is -33% |
| Key risksMDXG key risks include [1] its history of financial fraud allegations, Show more. |
Qualitative Assessment
AI Analysis | Feedback
MiMedx (MDXG) stock has lost about 25% since 2/28/2026 because of the following key factors:
1. MiMedx reported a significant deterioration in its Q1 2026 financial results, moving from profitability to a net loss. The company posted a GAAP net loss of $11 million, or $0.07 per share, compared to a GAAP net income of $7 million, or $0.05 per share, in the prior year period. Additionally, adjusted EBITDA turned negative at -$12 million, or 20% of net sales, a sharp decline from the positive $17 million, or 20% of net sales, reported in the same quarter last year. Total net sales also fell by 33% year-over-year to $59 million.
2. The company faced substantial headwinds in its wound care business due to adverse changes in Medicare reimbursement and issues with prior authorization processes. These challenges, specifically the shift from Average Sales Price (ASP) to a fixed-price cap for CMS reimbursement, the abrupt non-implementation of Local Coverage Determinations (LCDs), and a problematic WISeR prior-authorization rollout, severely impacted claims processing and provider utilization in the key wound care market.
Show more
MiMedx (MDXG) stock has lost about 25% since 2/28/2026 because of the following key factors:
1. MiMedx reported a significant deterioration in its Q1 2026 financial results, moving from profitability to a net loss. The company posted a GAAP net loss of $11 million, or $0.07 per share, compared to a GAAP net income of $7 million, or $0.05 per share, in the prior year period. Additionally, adjusted EBITDA turned negative at -$12 million, or 20% of net sales, a sharp decline from the positive $17 million, or 20% of net sales, reported in the same quarter last year. Total net sales also fell by 33% year-over-year to $59 million.
2. The company faced substantial headwinds in its wound care business due to adverse changes in Medicare reimbursement and issues with prior authorization processes. These challenges, specifically the shift from Average Sales Price (ASP) to a fixed-price cap for CMS reimbursement, the abrupt non-implementation of Local Coverage Determinations (LCDs), and a problematic WISeR prior-authorization rollout, severely impacted claims processing and provider utilization in the key wound care market.
3. Several financial analysts downgraded their price targets for MiMedx, reflecting a more cautious outlook following the challenging Q1 2026 results. For instance, Citizens lowered its price target from $10 to $7 on April 20, 2026, and further reduced it to $6 on April 30, 2026. Craig-Hallum also revised its price target from $10 to $7 on April 17, 2026, while maintaining a "Buy" rating.
4. An investor alert and investigation by the Pomerantz Law Firm were announced, potentially signaling legal scrutiny and contributing to investor uncertainty. On May 23, 2026, the Pomerantz Law Firm initiated an investigation into claims on behalf of investors of MiMedx Group, Inc., indicating potential concerns regarding the company's disclosures or practices.
Show less
Stock Movement Drivers
Fundamental Drivers
The -24.9% change in MDXG stock from 2/28/2026 to 6/21/2026 was primarily driven by a -32.1% change in the company's Net Income Margin (%).| (LTM values as of) | 2282026 | 6212026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.89 | 3.67 | -24.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 419 | 389 | -7.0% |
| Net Income Margin (%) | 11.6% | 7.9% | -32.1% |
| P/E Multiple | 14.9 | 17.7 | 19.1% |
| Shares Outstanding (Mil) | 148 | 148 | -0.2% |
| Cumulative Contribution | -24.9% |
Market Drivers
2/28/2026 to 6/21/2026| Return | Correlation | |
|---|---|---|
| MDXG | -24.9% | |
| Market (SPY) | 9.2% | 40.1% |
| Sector (XLV) | -6.4% | 44.5% |
Fundamental Drivers
The -46.7% change in MDXG stock from 11/30/2025 to 6/21/2026 was primarily driven by a -28.9% change in the company's P/E Multiple.| (LTM values as of) | 11302025 | 6212026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.88 | 3.67 | -46.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 393 | 389 | -1.0% |
| Net Income Margin (%) | 10.4% | 7.9% | -24.0% |
| P/E Multiple | 24.9 | 17.7 | -28.9% |
| Shares Outstanding (Mil) | 148 | 148 | -0.3% |
| Cumulative Contribution | -46.7% |
Market Drivers
11/30/2025 to 6/21/2026| Return | Correlation | |
|---|---|---|
| MDXG | -46.7% | |
| Market (SPY) | 9.9% | 34.2% |
| Sector (XLV) | -4.4% | 37.2% |
Fundamental Drivers
The -42.9% change in MDXG stock from 5/31/2025 to 6/21/2026 was primarily driven by a -30.9% change in the company's Net Income Margin (%).| (LTM values as of) | 5312025 | 6212026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.43 | 3.67 | -42.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 352 | 389 | 10.5% |
| Net Income Margin (%) | 11.4% | 7.9% | -30.9% |
| P/E Multiple | 23.6 | 17.7 | -24.7% |
| Shares Outstanding (Mil) | 147 | 148 | -0.8% |
| Cumulative Contribution | -42.9% |
Market Drivers
5/31/2025 to 6/21/2026| Return | Correlation | |
|---|---|---|
| MDXG | -42.9% | |
| Market (SPY) | 28.1% | 32.3% |
| Sector (XLV) | 14.6% | 27.8% |
Fundamental Drivers
The -37.4% change in MDXG stock from 5/31/2023 to 6/21/2026 was primarily driven by a -41.4% change in the company's P/S Multiple.| (LTM values as of) | 5312023 | 6212026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.86 | 3.67 | -37.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 281 | 389 | 38.8% |
| P/S Multiple | 2.4 | 1.4 | -41.4% |
| Shares Outstanding (Mil) | 114 | 148 | -22.9% |
| Cumulative Contribution | -37.4% |
Market Drivers
5/31/2023 to 6/21/2026| Return | Correlation | |
|---|---|---|
| MDXG | -37.4% | |
| Market (SPY) | 85.7% | 28.1% |
| Sector (XLV) | 22.9% | 23.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| MDXG Return | -33% | -54% | 215% | 10% | -30% | -47% | -60% |
| Peers Return | 16% | -32% | 22% | 1% | -5% | -5% | -12% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 8% | 98% |
Monthly Win Rates [3] | |||||||
| MDXG Win Rate | 67% | 33% | 67% | 50% | 17% | 17% | |
| Peers Win Rate | 56% | 40% | 58% | 48% | 48% | 37% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| MDXG Max Drawdown | -65% | -58% | -35% | -37% | -40% | -54% | |
| Peers Max Drawdown | -36% | -51% | -34% | -37% | -46% | -37% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ORGO, IART, SYK, VCEL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/18/2026 (YTD)
How Low Can It Go
| Event | MDXG | S&P 500 |
|---|---|---|
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -10.2% | -7.8% |
| % Gain to Breakeven | 11.4% | 8.5% |
| Time to Breakeven | 9 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -25.5% | -9.5% |
| % Gain to Breakeven | 34.2% | 10.5% |
| Time to Breakeven | 15 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -32.0% | -6.7% |
| % Gain to Breakeven | 47.1% | 7.1% |
| Time to Breakeven | 21 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -57.9% | -24.5% |
| % Gain to Breakeven | 137.5% | 32.4% |
| Time to Breakeven | 244 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -56.9% | -33.7% |
| % Gain to Breakeven | 131.9% | 50.9% |
| Time to Breakeven | 267 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -62.0% | -19.2% |
| % Gain to Breakeven | 163.5% | 23.8% |
| Time to Breakeven | 376 days | 105 days |
In The Past
MiMedx's stock fell -10.2% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 11.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | MDXG | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -25.5% | -9.5% |
| % Gain to Breakeven | 34.2% | 10.5% |
| Time to Breakeven | 15 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -32.0% | -6.7% |
| % Gain to Breakeven | 47.1% | 7.1% |
| Time to Breakeven | 21 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -57.9% | -24.5% |
| % Gain to Breakeven | 137.5% | 32.4% |
| Time to Breakeven | 244 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -56.9% | -33.7% |
| % Gain to Breakeven | 131.9% | 50.9% |
| Time to Breakeven | 267 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -62.0% | -19.2% |
| % Gain to Breakeven | 163.5% | 23.8% |
| Time to Breakeven | 376 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -25.8% | -12.2% |
| % Gain to Breakeven | 34.8% | 13.9% |
| Time to Breakeven | 60 days | 62 days |
| 2013 Taper Tantrum | ||
| % Loss | -43.0% | -0.2% |
| % Gain to Breakeven | 75.4% | 0.2% |
| Time to Breakeven | 90 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -25.4% | -17.9% |
| % Gain to Breakeven | 34.0% | 21.8% |
| Time to Breakeven | 137 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -25.9% | -15.4% |
| % Gain to Breakeven | 35.0% | 18.2% |
| Time to Breakeven | 50 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -90.6% | -53.4% |
| % Gain to Breakeven | 962.5% | 114.4% |
| Time to Breakeven | 1388 days | 1085 days |
In The Past
MiMedx's stock fell -10.2% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 11.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About MiMedx (MDXG)
MiMedx Group, Inc. (MDXG) is a biotechnology company focused on developing and distributing innovative solutions derived from human placental tissues. The company utilizes its patented and proprietary PURION process to convert these tissues into allografts, which are biological grafts from one human to another. This advanced processing method employs aseptic techniques alongside terminal sterilization to preserve the tissue's inherent biological properties and beneficial regulatory proteins, ensuring both efficacy and safety.
MiMedx offers a diverse portfolio of allograft products designed to address various medical needs. Its flagship products include EpiFix, a semi-permeable barrier membrane widely used for treating chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers. Other key products are AmnioFix, a semi-permeable barrier allograft for surgical recovery; EpiCord and AmnioCord, dehydrated human umbilical cord allografts that create a protective environment for healing in advanced wound care and surgical applications; and AMNIOBURN, specifically formulated for the treatment of partial and full-thickness burns. The company also offers mdHACM, a micronized powder form of AmnioFix.
The primary markets and customers for MiMedx's products are within critical healthcare sectors, including advanced wound care, burn treatment, surgical recovery, and non-operative sports medicine. Additionally, the company supplies allografts for dental applications on an original equipment manufacturer (OEM) basis. MiMedx primarily sells its products throughout the United States, utilizing a multi-channel distribution strategy that includes a direct sales force, independent sales agents, and independent distributors.
AI Analysis | Feedback
Here are 1-2 brief analogies for MiMedx (MDXG):
- Like a specialized Amgen (AMGN) for advanced tissue and wound repair.
- Similar to Organogenesis (ORGO), but focused on placental tissue products for healing.
AI Analysis | Feedback
- EpiFix: A semi-permeable protective barrier membrane used for treating chronic wounds like diabetic foot and pressure ulcers.
- AmnioFix: A semi-permeable protective barrier allograft made from dehydrated human amnion/chorion membrane for surgical recovery applications.
- EpiCord and AmnioCord: Dehydrated human umbilical cord allografts used to provide a protective environment for healing in advanced wound care and surgical recovery.
- AMNIOBURN: A semi-permeable protective barrier allograft specifically used in the treatment of partial-thickness and full-thickness burns.
- mdHACM: A micronized, powder form of AMNIOFIX.
AI Analysis | Feedback
MiMedx (MDXG) sells its products primarily to healthcare organizations and professionals rather than directly to individuals or a few named major corporate customers. Its sales approach, utilizing a direct sales force, independent sales agents, and distributors, indicates a broad customer base across various healthcare sectors. The major categories of customers it serves include:
- Hospitals and Surgical Centers: These institutions utilize MiMedx products for surgical recovery applications, burn treatment (e.g., AMNIOBURN), and advanced wound care within inpatient and outpatient settings.
- Specialized Wound Care Clinics: These facilities are key customers for products like EpiFix, which treats chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
- Sports Medicine and Orthopedic Clinics: These practices use MiMedx's allografts for non-operative sports medicine applications and surgical recovery.
AI Analysis | Feedback
AI Analysis | Feedback
Joseph H. Capper, Chief Executive Officer
Mr. Capper joined MiMedx in January 2023. He brings nearly 30 years of experience in MedTech and Life Sciences leadership roles. Mr. Capper previously served as CEO of BioTelemetry, where he led a significant turnaround that culminated in its acquisition by Royal Philips for $2.8 billion. Prior to BioTelemetry, he was President and CEO of both Home Diagnostics and CCS Medical. Earlier in his career, he held several leadership roles at Bayer AG and served as an officer in the U.S. Navy as a naval aviator.
Doug Rice, Chief Financial Officer
Mr. Rice joined MiMedx in July 2023. He has more than a decade of experience in the MedTech industry. Most recently, he served as the CFO of Orthofix Medical. Prior to Orthofix, Mr. Rice was CFO at Vision Source and held various finance leadership roles at McAfee and Concentra. He began his career at PricewaterhouseCoopers and is a Certified Public Accountant.
Ricci S. Whitlow, Chief Operating Officer
Ms. Whitlow joined MiMedx in January 2023. She brings over 30 years of Life Sciences and Pharmaceutical experience, with a background in operational leadership. Her prior roles include President, Clinical Supply Services at Catalent Pharma Solutions, and leadership positions at Optinose, LifeCell, Kinetic Concepts, and Johnson & Johnson.
Kim Moller, Chief Commercial Officer
Ms. Moller was promoted to Chief Commercial Officer in June 2024, having served as Senior Vice President of Sales since August 2020. She has nearly three decades of experience in sales leadership, including successfully executing strategic growth plans for prominent healthcare companies such as 3M and its subsidiaries Acelity and KCI.
William Frank Hulse, General Counsel and Chief Administrative Officer
Mr. Hulse joined MiMedx in December 2019, bringing over two decades of experience in large law firms and life sciences organizations, with significant legal, risk management, compliance, and operational expertise. Before MiMedx, he was a member of Dykema, a national law firm. Prior to that, he held various roles of increasing responsibility at Acelity, LP, Inc. (formerly Kinetic Concepts, Inc.), including Chief Compliance Officer and Senior Vice President for Enterprise Risk Management, Quality, and Regulatory, and also served as Division General Counsel.
AI Analysis | Feedback
The key risks to MiMedx (MDXG) primarily stem from its reliance on evolving healthcare reimbursement policies, the highly competitive nature of its market, and ongoing legal and intellectual property challenges.
- Medicare Reimbursement Changes: MiMedx faces significant uncertainty and potential market disruption due to upcoming changes in Medicare reimbursement policies, particularly the "2026 Regulatory Cliff" for its regenerative biomaterial products and skin substitutes. The Centers for Medicare and Medicaid Services (CMS) is implementing new payment approaches, including fixed reimbursement rates and adjustments to Local Coverage Determinations (LCDs), which are anticipated to lead to price pressure and a potential temporary stall in revenue growth. This regulatory shift is a major concern, as the company is highly dependent on the U.S. market. While MiMedx is proactively adapting its product mix and leveraging its platform to manage this transition, it remains a significant near-term headwind, impacting 2026 revenue guidance.
- Intense Market Competition: The regenerative medicine and wound care industries in which MiMedx operates are highly competitive. The company competes with numerous established tissue processors, medical device manufacturers, and new entrants, some of whom offer high-priced, clinically unproven skin substitutes. This intense competition can lead to customer and sales force attrition and necessitates continuous innovation and product differentiation for MiMedx to maintain its market share. Changes in CMS policies, such as the withdrawal of certain LCDs, could also intensify competitive pressures.
- Legal and Intellectual Property (IP) Challenges: MiMedx has a history of legal disputes, including ongoing litigation with competitors and former employees, which results in increased general and administrative expenses and poses risks to the company's reputation. The company’s business relies on its proprietary PURION process and an extensive patent portfolio, which it actively defends through lawsuits against alleged infringers. However, the ability to fully protect its intellectual property is uncertain, and there is an inherent risk of becoming subject to infringement claims from other parties. While past favorable rulings demonstrate their commitment to IP defense, ongoing legal battles can consume significant financial and management resources.
AI Analysis | Feedback
AI Analysis | Feedback
AI Analysis | Feedback
- Expansion and Diversification of Surgical Business: MiMedx is focusing on expanding its surgical applications, with the surgical segment demonstrating strong growth, including a 20% increase for the full year 2025 and 25% growth in Q4 2025. This expansion is supported by new commercial hires and recent portfolio additions, such as AmnioFix Thyroid Shield and the licensing of three 510(k)-cleared products for surgical applications, targeting high-growth specialties.
- Launch and Uptake of New Products: The company's wound care segment has experienced strong growth, driven by the successful uptake of recently launched products like EpiExpress and Emerge. MiMedx also plans to continue innovating and diversifying its product portfolio in 2026.
- Continued Investment in Research and Development (R&D) and Clinical Evidence: MiMedx views scientific research as a crucial element of its growth strategy, continuing investments in R&D. This includes ongoing clinical trials, such as a near-completed randomized controlled trial (RCT) for EpiEffect and a planned new RCT for ChorioFix, aimed at long-term differentiation in clinical efficacy.
- Adaptation and Stabilization within the Wound Care Market: Despite near-term disruptions due to Medicare reimbursement changes, MiMedx anticipates a sequential increase in revenue throughout 2026 as the wound care market adjusts and stabilizes. The company expects to recover to historical double-digit top-line growth by 2027, confident in its ability to compete effectively within the new reimbursement framework.
AI Analysis | Feedback
Share Repurchases
- MiMedx's Board of Directors authorized a share repurchase program of up to $100 million over a two-year period, announced on February 25, 2026.
- This program is intended to return capital to shareholders while maintaining flexibility for organic investment and potential mergers and acquisitions.
Share Issuance
- On March 10, 2026, the Chief Commercial Officer acquired 42,845 shares through the vesting of performance stock units, with 21,270 shares withheld for tax obligations.
- The Chief Financial Officer acquired 243,000 shares upon the vesting of performance stock units covering the period from January 1, 2023, to December 31, 2025, with 96,363 shares disposed of to satisfy tax obligations.
- On March 4, 2026, the Chief Executive Officer was awarded 371,094 shares of common stock as restricted stock.
Outbound Investments
- MiMedx's acquisitions amounted to $3.1 million in Q3 2025.
- The total annual value of acquisitions for fiscal year 2024 was $7.9 million.
- The highest quarterly value for acquisitions in the past five years was $5.0 million during Q1 2024.
Capital Expenditures
- Capital expenditures in the most recent quarter totaled -$0.29 million.
- In the last 12 months, capital expenditures were -$1.03 million.
- Projected capital expenditures are $4 million for 2025 and $5 million for 2026, with an expected focus on long-term assets and infrastructure.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| MiMedx Earnings Notes | 12/16/2025 | |
| How Low Can MiMedx Stock Really Go? | 10/17/2025 | |
| MiMedx (MDXG) Debt Comparison | 08/08/2025 | |
| MiMedx (MDXG) Operating Cash Flow Comparison | 08/08/2025 | |
| MiMedx (MDXG) EBITDA Comparison | 08/08/2025 | |
| MiMedx (MDXG) Net Income Comparison | 08/08/2025 | |
| MiMedx (MDXG) Tax Expense Comparison | 08/08/2025 | |
| MiMedx (MDXG) Operating Income Comparison | 08/08/2025 | |
| MiMedx (MDXG) Revenue Comparison | 08/08/2025 | |
| Why MiMedx Stock Moved: MDXG Stock Has Gained 156% Since 2022 Fiscal End, Primarily Due To Favorable Change In Price To Sales Multiple (P/S) | 08/08/2025 | |
| ARTICLES | ||
| Stocks Trading At 52-Week Low | 04/17/2026 |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 17.58 |
| Mkt Cap | 1.4 |
| Rev LTM | 513 |
| Op Inc LTM | 40 |
| FCF LTM | 47 |
| FCF 3Y Avg | 14 |
| CFO LTM | 71 |
| CFO 3Y Avg | 58 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.5% |
| Rev Chg 3Y Avg | 10.1% |
| Rev Chg Q | 2.4% |
| QoQ Delta Rev Chg LTM | 0.6% |
| Op Inc Chg LTM | 37.9% |
| Op Inc Chg 3Y Avg | 82.7% |
| Op Mgn LTM | 5.4% |
| Op Mgn 3Y Avg | 2.8% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 18.1% |
| CFO/Rev 3Y Avg | 15.9% |
| FCF/Rev LTM | 16.3% |
| FCF/Rev 3Y Avg | 4.8% |
Price Behavior
| Market Price | $3.67 | |
| Market Cap ($ Bil) | 0.5 | |
| First Trading Date | 06/24/2008 | |
| Distance from 52W High | -53.9% | |
| 50 Days | 200 Days | |
| DMA Price | $3.60 | $5.48 |
| DMA Trend | down | down |
| Distance from DMA | 2.0% | -33.0% |
| 3M | 1YR | |
| Volatility | 51.7% | 43.2% |
| Downside Capture | 190.31 | 175.87 |
| Upside Capture | 62.36 | 73.49 |
| Correlation (SPY) | 33.3% | 31.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.58 | 1.49 | 1.50 | 1.19 | 1.16 | 0.85 |
| Up Beta | 0.64 | 2.31 | 1.78 | 1.49 | 1.29 | 0.74 |
| Down Beta | -1.03 | -4.23 | 0.93 | 0.51 | 0.92 | 0.80 |
| Up Capture | 126% | 53% | 57% | 30% | 54% | 47% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 13 | 21 | 28 | 52 | 107 | 351 |
| Down Capture | 29% | 368% | 230% | 196% | 150% | 105% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 7 | 18 | 32 | 68 | 133 | 380 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MDXG | |
|---|---|---|---|---|
| MDXG | -39.8% | 42.9% | -1.07 | - |
| Sector ETF (XLV) | 14.0% | 15.0% | 0.66 | 28.4% |
| Equity (SPY) | 26.5% | 12.4% | 1.61 | 32.8% |
| Gold (GLD) | 24.2% | 27.5% | 0.77 | 12.6% |
| Commodities (DBC) | 19.8% | 18.8% | 0.83 | -20.5% |
| Real Estate (VNQ) | 11.0% | 13.7% | 0.52 | 19.3% |
| Bitcoin (BTCUSD) | -40.0% | 42.4% | -1.08 | 16.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MDXG | |
|---|---|---|---|---|
| MDXG | -20.4% | 62.0% | -0.08 | - |
| Sector ETF (XLV) | 5.4% | 14.7% | 0.19 | 28.2% |
| Equity (SPY) | 13.5% | 17.1% | 0.62 | 34.5% |
| Gold (GLD) | 17.1% | 18.3% | 0.76 | 3.5% |
| Commodities (DBC) | 7.5% | 19.4% | 0.29 | -0.3% |
| Real Estate (VNQ) | 1.9% | 18.9% | 0.00 | 29.3% |
| Bitcoin (BTCUSD) | 11.0% | 54.2% | 0.40 | 14.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with MDXG | |
|---|---|---|---|---|
| MDXG | -14.5% | 67.6% | 0.06 | - |
| Sector ETF (XLV) | 9.4% | 16.6% | 0.46 | 24.4% |
| Equity (SPY) | 15.3% | 18.0% | 0.73 | 28.8% |
| Gold (GLD) | 12.3% | 16.1% | 0.63 | 3.9% |
| Commodities (DBC) | 5.9% | 18.0% | 0.26 | 6.1% |
| Real Estate (VNQ) | 5.3% | 20.7% | 0.22 | 24.4% |
| Bitcoin (BTCUSD) | 60.0% | 66.8% | 1.00 | 7.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/16/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/29/2026 | 8.9% | 18.6% | 19.3% |
| 2/25/2026 | -6.4% | -8.7% | -25.4% |
| 10/29/2025 | 2.9% | 10.7% | -7.2% |
| 7/30/2025 | 10.3% | 11.0% | 10.1% |
| 4/30/2025 | -8.1% | 1.5% | -6.5% |
| 2/26/2025 | 1.6% | 0.9% | -3.4% |
| 10/30/2024 | 20.4% | 31.8% | 62.6% |
| 7/31/2024 | -10.3% | -15.8% | -10.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 14 | 14 | 11 |
| # Negative | 10 | 10 | 13 |
| Median Positive | 7.3% | 10.9% | 20.5% |
| Median Negative | -5.1% | -8.1% | -7.2% |
| Max Positive | 39.4% | 55.9% | 62.6% |
| Max Negative | -13.0% | -15.8% | -29.1% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/29/2026 | 8.9% | 18.6% | 19.3% |
| 2/25/2026 | -6.4% | -8.7% | -25.4% |
| 10/29/2025 | 2.9% | 10.7% | -7.2% |
| 7/30/2025 | 10.3% | 11.0% | 10.1% |
| 4/30/2025 | -8.1% | 1.5% | -6.5% |
| 2/26/2025 | 1.6% | 0.9% | -3.4% |
| 10/30/2024 | 20.4% | 31.8% | 62.6% |
| 7/31/2024 | -10.3% | -15.8% | -10.2% |
| 4/30/2024 | 18.7% | 18.3% | 15.6% |
| 2/28/2024 | -0.5% | -1.6% | -6.1% |
| 10/30/2023 | 3.8% | 5.9% | 23.1% |
| 8/1/2023 | -2.9% | -7.6% | -7.2% |
| 5/2/2023 | 39.4% | 55.9% | 52.0% |
| 2/28/2023 | -13.0% | -12.7% | -29.1% |
| 1/9/2023 | 2.2% | 5.6% | 46.4% |
| 11/2/2022 | 5.4% | 5.1% | 23.2% |
| 8/2/2022 | 7.3% | 19.2% | 2.6% |
| 5/3/2022 | 7.3% | -15.4% | -8.1% |
| 2/28/2022 | -0.6% | -4.4% | -2.0% |
| 1/10/2022 | -2.8% | -9.1% | -17.4% |
| 11/2/2021 | 15.1% | 16.1% | -0.7% |
| 8/3/2021 | -5.3% | -4.9% | 20.5% |
| 4/28/2021 | -4.9% | -6.2% | -4.2% |
| 8/4/2020 | 0.0% | 0.0% | 0.0% |
| SUMMARY STATS | |||
| # Positive | 14 | 14 | 11 |
| # Negative | 10 | 10 | 13 |
| Median Positive | 7.3% | 10.9% | 20.5% |
| Median Negative | -5.1% | -8.1% | -7.2% |
| Max Positive | 39.4% | 55.9% | 62.6% |
| Max Negative | -13.0% | -15.8% | -29.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 04/29/2026 | 10-Q |
| 12/31/2025 | 02/25/2026 | 10-K |
| 09/30/2025 | 10/29/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 04/30/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 10/30/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 04/30/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 10/30/2023 | 10-Q |
| 06/30/2023 | 08/01/2023 | 10-Q |
| 03/31/2023 | 05/02/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/02/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 04/29/2026 | 10-Q |
| 12/31/2025 | 02/25/2026 | 10-K |
| 09/30/2025 | 10/29/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 04/30/2025 | 10-Q |
| 12/31/2024 | 02/26/2025 | 10-K |
| 09/30/2024 | 10/30/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 04/30/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 10/30/2023 | 10-Q |
| 06/30/2023 | 08/01/2023 | 10-Q |
| 03/31/2023 | 05/02/2023 | 10-Q |
| 12/31/2022 | 02/28/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/02/2022 | 10-Q |
| 03/31/2022 | 05/03/2022 | 10-Q |
| 12/31/2021 | 02/28/2022 | 10-K |
| 09/30/2021 | 11/02/2021 | 10-Q |
| 06/30/2021 | 08/03/2021 | 10-Q |
| 03/31/2021 | 04/28/2021 | 10-Q |
| 12/31/2020 | 03/08/2021 | 10-K |
| 09/30/2020 | 11/04/2020 | 10-Q |
| 06/30/2020 | 08/04/2020 | 10-Q |
| 03/31/2020 | 07/06/2020 | 10-Q |
| 12/31/2019 | 07/06/2020 | 10-K |
| 09/30/2019 | 07/06/2020 | 10-Q |
| 06/30/2019 | 07/06/2020 | 10-Q |
Recent Forward Guidance
Updated 6/1/2026Latest: Q1 2026 Earnings Reported 4/29/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 260.00 Mil | 275.00 Mil | 290.00 Mil | -21.4% | Lowered | Guidance: 350.00 Mil for 2026 | |
| 2026 Revenue Growth | 10.0% | -16.7% | -2.0% | Lowered | Guidance: 12.0% for 2026 | ||
| 2026 Operating Margin | 20.0% | 14.3% | 2.5% | Raised | Guidance: 17.5% for 2026 | ||
Prior: Q4 2025 Earnings Reported 2/25/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 340.00 Mil | 350.00 Mil | 360.00 Mil | Higher New | |||
| 2026 Operating Margin | 20.0% | 21.0% | -6.7% | -1.5% | Lowered | Guidance: 22.5% for 2025 | |
| 2026 Revenue Growth | 12.0% | 9.1% | 1.0% | Raised | Guidance: 11.0% for 2025 | ||
Insider Activity
Updated 6/12/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Maersk-Moller, Kimberly | Chief Commercial Officer | Direct | Sell | 11102025 | 7.42 | 58,300 | 432,329 | 1,757,364 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Maersk-Moller, Kimberly | Chief Commercial Officer | Direct | Sell | 11102025 | 7.42 | 58,300 | 432,329 | 1,757,364 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.